EUVIMEDEUVIMED entdecken
Crossref

The ALS drug riluzole binds to the C-terminal domain of SARS-CoV-2 nucleocapsid protein and has antiviral activity

María Ángeles Márquez-Moñino, Clara M Santiveri, Patricia de León, Sergio Camero, Ramón Campos-Olivas, M Ángeles Jiménez, Margarita Sáiz, Beatriz González, José Manuel Pérez-Cañadillas

Structure · 2025-01 · 33 (1) · 39-50.e6

DOI: 10.1016/j.str.2024.10.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Structure, 2025-01. Verfasst von María Ángeles Márquez-Moñino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physical-Chemistry "Blas Cabrera", CSIC, C/ Serrano 119, 28006 Madrid, Spain. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Riluzole, Protein Binding. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Ministerio de Ciencia e Innovación, Centro Nacional de Investigaciones Oncológicas, Consejo Superior de Investigaciones Científicas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsRiluzoleProtein BindingBinding SitesHumansCrystallography, X-RayCoronavirus Nucleocapsid ProteinsPhosphoproteinsProtein DomainsCOVID-19 Drug TreatmentModels, Molecular

Stichwörter der Autor:innen

(19)F NMRCVL218SARS-CoV-2X-ray structureantiviral activitybenzothiazol derivatescomputational dockingfragment-based drug discoverynucleocapsidriluzole

Substanzen

Antiviral AgentsRiluzoleCoronavirus Nucleocapsid ProteinsPhosphoproteinsnucleocapsid phosphoprotein, SARS-CoV-2

Autor:innen und Institutionen

  • Institute of Physical-Chemistry "Blas Cabrera", CSIC, C/ Serrano 119, 28006 Madrid, Spain.
  • Spectroscopy and Nuclear Magnetic Resonance Unit, Structural Biology Programme, Spanish National Cancer Research Centre, C/ Melchor Fernández Almagro 3, 28029 Madrid, Spain.
  • Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Universidad Autónoma de Madrid, c/ Nicolás Cabrera nº 1, 28049 Madrid, Spain.
  • Institute of Physical-Chemistry "Blas Cabrera", CSIC, C/ Serrano 119, 28006 Madrid, Spain. Electronic address: xbeatriz@iqf.csic.es.
  • Institute of Physical-Chemistry "Blas Cabrera", CSIC, C/ Serrano 119, 28006 Madrid, Spain. Electronic address: jmperez@iqfr.csic.es.

Förderung

  • Ministerio de Ciencia e Innovación
  • Centro Nacional de Investigaciones Oncológicas
  • Consejo Superior de Investigaciones Científicas
  • State Agency of Research
  • European Regional Development Fund

Zitieren

APA

Márquez-Moñino, M. Á., Santiveri, C. M., de León, P., Camero, S., Campos-Olivas, R., Jiménez, M. Á., Sáiz, M., González, B., & Pérez-Cañadillas, J. M. (2025). The ALS drug riluzole binds to the C-terminal domain of SARS-CoV-2 nucleocapsid protein and has antiviral activity. Structure, 33(1), 39-50.e6. https://doi.org/10.1016/j.str.2024.10.025

Vancouver

Márquez-Moñino MÁ, Santiveri CM, de León P, Camero S, Campos-Olivas R, Jiménez MÁ, et al. The ALS drug riluzole binds to the C-terminal domain of SARS-CoV-2 nucleocapsid protein and has antiviral activity. Structure. 2025;33(1):39-50.e6. doi:10.1016/j.str.2024.10.025

BibTeX
@article{MrquezMoino2025,
  author = {Márquez-Moñino, María Ángeles and Santiveri, Clara M and de León, Patricia and Camero, Sergio and Campos-Olivas, Ramón and Jiménez, M Ángeles and Sáiz, Margarita and González, Beatriz and Pérez-Cañadillas, José Manuel},
  title = {The ALS drug riluzole binds to the C-terminal domain of SARS-CoV-2 nucleocapsid protein and has antiviral activity},
  journal = {Structure},
  year = {2025},
  volume = {33},
  number = {1},
  pages = {39--50.e6},
  doi = {10.1016/j.str.2024.10.025}
}
Kostenlos starten →